Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.76 USD
Change Today +0.13 / 1.22%
Volume 107.3K
DRNA On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 2:32 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

dicerna pharmaceuticals inc (DRNA) Snapshot

Open
$10.50
Previous Close
$10.63
Day High
$11.78
Day Low
$10.50
52 Week High
03/17/15 - $27.33
52 Week Low
11/6/14 - $8.00
Market Cap
221.6M
Average Volume 10 Days
129.0K
EPS TTM
$-3.10
Shares Outstanding
20.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DICERNA PHARMACEUTICALS INC (DRNA)

Related News

No related news articles were found.

dicerna pharmaceuticals inc (DRNA) Related Businessweek News

No Related Businessweek News Found

dicerna pharmaceuticals inc (DRNA) Details

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherited diseases involving genes expressed in the liver. It is also developing DCR-MYC, which is in Phase I clinical study for the treatment of various cancers in patients with solid tumors, multiple myeloma, or lymphoma, as well as in Phase Ib/II clinical trial to treat cancer in patients with advanced hepatocellular carcinoma. In addition, the company is developing KRAS oncogene, a gene that is mutated in various cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer; and a therapeutic targeting a second cancer-related gene. It has a license agreement with City of Hope, an academic research and medical center to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans; licensing and collaboration agreement with Tekmira Pharmaceuticals Corporation to license LNP delivery technology for use in PH1 development program; and a license agreement with Plant Bioscience Limited to research, discover, develop, manufacture, sell, import, and export products incorporating short RNA molecules. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

42 Employees
Last Reported Date: 03/12/15
Founded in 2006

dicerna pharmaceuticals inc (DRNA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $430.0K
Chief Financial Officer
Total Annual Compensation: $65.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $335.0K
Chief Medical Officer
Total Annual Compensation: $269.1K
Chief Business Officer
Total Annual Compensation: $295.0K
Compensation as of Fiscal Year 2014.

dicerna pharmaceuticals inc (DRNA) Key Developments

Dicerna Pharmaceuticals Submits Investigational New Drug Application to FDA for Hyperoxaluria Type 1 Drug

Dicerna Pharmaceuticals announced that it has submitted an investigational new drug application to the U.S. Food and Drug Administration for CR-PH1, the therapeutic candidate for the treatment of primary hyperoxaluria type 1, a severe, rare, inherited disorder of the liver that often results in kidney failure. There are no approved therapies for PH1.

Dicerna Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Financial Guidance for the Year 2015

Dicerna Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of USD 0.184 million. Loss from operations was USD 16.210 million compared to USD 11.178 million a year ago. Net loss was USD 16.176 million compared to USD 11.355 million a year ago. Net loss attributable to common stockholders was USD 16.176 million compared to USD 11.355 million a year ago. Basic and diluted net loss per share allocable to common stockholders was USD 0.86 compared to USD 0.64 a year ago. Non-GAAP loss per share - basic and diluted was USD 0.72 compared to USD 0.51 a year ago. Non-GAAP net loss was USD 13.515 million compared to USD 8.950 million a year ago. For the six months, the company reported revenues of USD 0.184 million. Loss from operations was USD 30.347 million compared to USD 19.270 million a year ago. Net loss was USD 30.260 million compared to USD 22.159 million a year ago. Net loss attributable to common stockholders was USD 30.260 million compared to USD 22.363 million a year ago. Basic and diluted net loss per share allocable to common stockholders was USD 1.65 compared to USD 1.57 a year ago. Non-GAAP loss per share - basic and diluted was USD 1.38 compared to USD 1.05 a year ago. Non-GAAP net loss was USD 25.279 million compared to USD 14.983 million a year ago. The Company expects that it has sufficient cash to fund operations for at least the next twelve months. This estimate assumes no additional funding from new partnership agreements or debt or equity financing events.

European Medicines Agency Grants Orphan Drug Designation to Dicerna Pharmaceuticals, Inc.'s DCR-PH

Dicerna Pharmaceuticals, Inc. announced that the European Medicines Agency granted Orphan Drug Designation to DCR-PH1, the company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1). PH1 is a severe, rare, inherited disorder of the liver that often results in kidney failure and for which there are no approved therapies. Orphan Drug Designation by the EMA provides regulatory and financial incentives under Regulation (EC) No. 141/2000 for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union, and for which no satisfactory treatment is available. In addition to a 10-year period of marketing exclusivity in the EU after product approval, Orphan Drug Designation provides incentives for companies seeking protocol assistance from the EMA during the product development phase and direct access to the centralized marketing authorization procedure. DCR-PH1 is Dicerna's proprietary therapeutic candidate in development for the treatment of PH1. Preclinical experiments indicate that DCR-PH1 knocks down hydroxyacid oxalyase-1 (HAO1), the gene transcript that encodes for the enzyme glycolate oxidase (GO), which, in turn, reduces the excretion of oxalate in the urine. DCR-PH1 incorporates a proprietary, lipid nanoparticle technology that allows for efficient delivery to the liver after intravenous administration. Dicerna obtained rights to this delivery technology by way of a licensing agreement with Tekmira Pharmaceuticals Corporation signed in November 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRNA:US $10.76 USD +0.13

DRNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arbutus Biopharma Corp $6.96 USD +0.03
Benitec Biopharma Ltd A$0.51 AUD -0.015
Galena Biopharma Inc $1.53 USD -0.09
Marina Biotech Inc $0.39 USD -0.03
Silence Therapeutics PLC 257.50 GBp -2.50
View Industry Companies
 

Industry Analysis

DRNA

Industry Average

Valuation DRNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,161.9x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 752.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DICERNA PHARMACEUTICALS INC, please visit www.dicerna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.